54044-11-0

Basic information

• Product Name: 3-AZETIDINONE
• Synonyms: 3-AZETIDINONE;3-Oxoazetidine
• CAS NO: 54044-11-0
• Molecular Formula: C3H5NO
• Molecular Weight: 71.08
• Mol File: 54044-11-0.mol

Chemical Properties

• Boiling Point: 140℃
• Flash Point: 77℃
• Appearance: /
• Density: 1.119
• Storage Temp.: 2-8°C(protect from light)
• PKA: 5.80±0.20(Predicted)
• CAS DataBase Reference: 3-AZETIDINONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AZETIDINONE(54044-11-0)
• EPA Substance Registry System: 3-AZETIDINONE(54044-11-0)

Safety Data

• Hazardous Substances Data: 54044-11-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Azetidinone is used as a key chemical intermediate for the synthesis of beta-lactam antibiotics, which are essential in treating a wide range of bacterial infections. Its unique structure allows for the formation of different functional groups, making it a valuable building block in the development of new drugs.
Used in Organic Synthesis:
3-Azetidinone is used as a versatile building block in organic synthesis, enabling the formation of various functional groups through different chemical reactions. This property makes it an important component in the preparation of chiral compounds, which are crucial in the development of new drugs and other chemical products.
Used in Cancer Treatment Research:
3-Azetidinone has been studied for its potential therapeutic applications, including the treatment of cancer and other diseases. Its unique structure and reactivity make it a promising candidate for the development of novel therapeutic agents.
Used as a Chiral Building Block:
3-Azetidinone is used as a chiral building block in the preparation of chiral compounds, which are important in the development of new drugs and other chemical products. Its ability to form different functional groups and its unique structure make it a valuable component in the synthesis of enantiomerically pure compounds.

Upstream product

• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 

Downstream Products

• 105258-88-6 3-oxo-azetidine-1-carboxylic acid ethyl ester 

Relevant articles and documents

Preparation method of medicine intermediate 1 -tert-butoxycarbonyl -3 -azetidinone (by machine translation)

The invention relates to the technical field of organic chemistry, and concretely relates 1 - tert-butyloxycarbonyl -3 -azetidinone and a preparation method thereof. Wherein R1 Is C1 - C6 Alkyl groups and R2 And R3 Is H or C1 - C6 The alkyl group and the acid are organic acids or inorganic acids. The method is high in relative yield and high in industrial amplification production applicability. (by machine translation)

Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability

Cannabidiol is the nonpsychoactive natural component of C. sativa that has been shown to be neuroprotective in multiple animal models. Our interest is to advance a therapeutic candidate for the orphan indication hepatic encephalopathy (HE). HE is a serious neurological disorder that occurs in patients with cirrhosis or liver failure. Although cannabidiol is effective in models of HE, it has limitations in terms of safety and oral bioavailability. Herein, we describe a series of side chain modified resorcinols that were designed for greater hydrophilicity and "drug likeness", while varying hydrogen bond donors, acceptors, architecture, basicity, neutrality, acidity, and polar surface area within the pendent group. Our primary screen evaluated the ability of the test agents to prevent damage to hippocampal neurons induced by ammonium acetate and ethanol at clinically relevant concentrations. Notably, KLS-13019 was 50-fold more potent and >400-fold safer than cannabidiol and exhibited an in vitro profile consistent with improved oral bioavailability.

NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY

Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.

Catalytic Enantioselective Intermolecular Desymmetrization of Azetidines

The first catalytic asymmetric desymmetrization of azetidines is disclosed. Despite the low propensity of azetidine ring opening and challenging stereocontrol, smooth intermolecular reactions were realized with excellent efficiency and enantioselectivity.

NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY

Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.

OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (Ia) and Formula (Ib) as follows: wherein Y, Z, and n are defined herein; and wherein Yb and Zb are as defined herein.